Press Releases2017-09-13T20:17:34+00:00

Press Releases

Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for Sanofi/Regeneron’s Dupixent, but Insurance Coverage and Out-of-Pocket Costs Continue to be Key Barriers for the Only Approved Atopic Dermatitis Biologic

According to the latest update from Spherix Global Insights, while dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis. Download Report Overview EXTON, Pa., August 15, 2018 /PRNewswire/ — Sanofi/Regeneron’s Dupixent continues to exceed expectations and current users remain extremely satisfied with the first biologic approved to treat moderate-to-severe atopic dermatitis, according to 100 U.S. dermatologists surveyed in July 2018. With nearly eighteen months on the market, the majority of Dupixent users report prescribing the agent to more than five atopic dermatitis patients, [...]

August 15, 2018|

Spherix Global Insights Announces Real World Audit Abstracts Accepted for Presentation at the 34th Congress of ECTRIMS In Berlin, Germany

The two abstracts compare U.S. neurologists' self-reported perceptions with actual prescribing behavior to assess if the use of highly effective therapies as first-line treatment is increasing over time and what disease metrics and treatment expectations drive the selection of monoclonal antibody agents in patients recently switched to a new therapy EXTON, Pa., Aug. 7, 2018 /PRNewswire/ -- Spherix Global Insights, an independent business intelligence and market research company, today announced that two abstracts based upon real world data collected as part of their multiple sclerosis (MS) patient chart audits have been accepted for presentation at the 34th Congress of the [...]

August 7, 2018|

Pfizer’s Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market

Two-thirds of surveyed nephrologists do not expect their dialysis center to make Retacrit available for at least a year, if ever, according to the latest quarterly anemia report by Spherix Global Insights Download Report Overview EXTON, Pa., July 31, 2018 /PRNewswire/ -- Plagued by regulatory delays, the FDA finally granted approval for Retacrit in May 2018, making it the first biosimilar erythropoietin-stimulating agent (ESA) to become available in the US market. Vifor Pharma, which also holds exclusive US commercialization rights to Roche's Mircera, a long-acting ESA, will be responsible for Retacrit commercialization in the US dialysis setting. A survey of [...]

July 31, 2018|

Analysis of Over 1,000 Systemic Lupus Erythematosus Patients Reveals Real World Patient Populations are Not Representative of Clinical Trial Samples

While the systemic lupus erythematosus (SLE) pipeline has progressed with agents such as Janssen's Stelara, AstraZeneca/MedImmune's anifrolumab, Neovacs' INF-K, and ImmuPharma's Lupuzor, historically, most agents in development do not make it past phase III trials, resulting in an exceptionally high unmet need. Download Report Overview EXTON, Pa., July 25, 2018 /PRNewswire/ -- To better understand what "real world" SLE patients look like in terms of disease burden, physician touchpoints, and treatment journeys, Spherix Global Insights collaborated with 201 US rheumatologists to analyze the records of 1,032 SLE patients who are currently being treated with or who are candidates for systemic [...]

July 25, 2018|

Amgen’s Parsabiv Doubles in Most Recent Quarter But Strict Usage Guidelines from Large Dialysis Organizations, DaVita and Fresenius Medical Care, Stifle Potential

The majority of nephrologists intend to increase their use of Parsabiv in the next quarter, but access at dialysis units proves to be the greatest barrier, according to a new report released by Spherix Global Insights Download Report Overview EXTON, Pa., July 24, 2018 /PRNewswire/ – Nephrologists largely believe that an IV calcimimetic (e.g. Parsabiv) will improve outcomes in secondary hyperparathyroidism. So, why the muted uptake? According to a survey of over 200 US nephrologists in June 2018, one of the leading barriers is restrictive protocols put in place by large dialysis organizations (LDOs) such as DaVita and Fresenius Medical [...]

July 24, 2018|

Recent Chart Audit of New Start Multiple Sclerosis Patients Confirms Dominance of the Oral Class, including Biogen’s Tecfidera, for First-Line Treatment But Finds Monoclonal Antibody Therapies, such as Genentech’s Ocrevus, Emerging as Legitimate Competitors

Teva’s Copaxone remains the brand share leader among new start patients year-over-year, although neurologists are beginning to write prescriptions for Mylan’s generic glatiramer acetate and Sandoz’s Glatopa independent of direct payer influence, according to a recently published independent audit from Spherix Global Insights Download Report Overview EXTON, Pa., July 23, 2018 /PRNewswire/ — The oral disease-modifying therapies (DMTs) dominate the first-line position among multiple sclerosis (MS) patients recently started on their first DMT, with one in five oral DMT starts driven primarily by the preference for an oral formulation, according to the second annual edition of Spherix Global Insights’ new [...]

July 23, 2018|